Systematic review with meta‐analysis: high mortality in patients with non‐severe alcoholic hepatitis by Bennett, K et al.
1 
 
Systematic review and meta-analysis: high mortality in patients with non-
severe alcoholic hepatitis  
 
Short title: Mortality of non-severe alcoholic hepatitis 
  
Kris Bennett1,2, Doyo G Enki3, Mark Thursz4, Matthew E Cramp1,2, Ashwin D Dhanda1,2 
 
1Institute of Translational and Stratified Medicine, University of Plymouth, UK 
2South West Liver Unit, University Hospitals Plymouth NHS Trust, Plymouth, UK 
3Medical Statistics Group, University of Plymouth, UK 





Dr Ashwin Dhanda 
South West Liver Unit 
Level 7, Derriford Hospital, Plymouth, PL6 8DH 
United Kingdom 
Email: ashwin.dhanda@plymouth.ac.uk 
Telephone: +44 (0)1752 432723 












KB, AD: performed systematic review; DE: statistical analysis; AD: drafted manuscript; AD, 







Alcoholic hepatitis is a serious complication of alcohol misuse. Severe alcoholic hepatitis 
with its high mortality, has been investigated in detail but ‘non-severe alcoholic hepatitis’ is 
poorly characterised. Survival of this group of patients is unknown.  
 
Aim 
To conduct a systematic review and meta-analysis to determine 28-day, 90-day and 1-year 
mortality of patients with non-severe alcoholic hepatitis. 
 
Methods 
The protocol was registered on the PROSPERO database (CRD42018107451). Embase, 
Medline and Cochrane Central databases were searched until July 2018. All study designs 
reporting mortality rates in patients with non-severe alcoholic hepatitis were eligible. Mortality 
data were extracted and meta-analysis performed using a random effects model. Risk of 
bias was assessed by Cochrane risk of bias or National Institutes of Health quality 
assessment tool for case series studies. 
 
Results 
Twenty-five studies (n=1372 patients; 12 prospective) met criteria. Twenty-eight day 
mortality (17 studies; n=993) was 6% (95% CI 3-9%; I2=67.3%; p<0.001), 90-day mortality 
(15 studies; n=755) was 7% (4-11%, I2=64.2%; p<0.001) and 1-year mortality (five studies; 
n=234) was 13% (4-24%; I2=72%; p=0.006). Subgroup analyses by method of diagnosis 
(histological versus clinical) or study design (prospective versus retrospective) did not reveal 
differences in mortality. 
 
Conclusion 
Non-severe alcoholic hepatitis is not benign with 6% and 13% 28-day and 1-year mortality, 
respectively. This systematic review demonstrates the paucity of high quality studies in 
patients with non-severe alcoholic hepatitis. Our analysis suggests that patients who do not 
meet criteria for severe alcoholic hepatitis are an important and hitherto overlooked clinical 
group. Full characterisation of clinical outcome and development of treatment strategies to 
reduce mortality in this group is a priority. 
 
Keywords 







Alcoholic hepatitis is a serious complication of alcohol-related liver disease characterised by 
recent onset jaundice and coagulopathy in heavy long-term alcohol consumers.1 Its 
incidence in Europe is increasing2, 3 and it accounts for approximately 0.7% of unplanned 
hospital admissions in USA.4  
 
Analysis of the seminal randomised controlled trial (RCT) of corticosteroids by Maddrey in 
19785 determined that corticosteroid treatment was of most benefit in the 15 patients with 
severe disease defined by a discriminant function (DF) based on bilirubin and prothrombin 
time with a threshold of 93. All 40 patients with DF < 93 survived. The threshold was 
subsequently modified to 32 to take into account inter-laboratory variation in prothrombin 
time measurement.6 It has since been assumed that patients with DF < 32 have a good 
prognosis. This threshold has been applied to classify severe disease and has been adopted 
both in clinical guidelines as a treatment trigger7, 8 and as a clinical trial inclusion criterion.9 A 
recent expert review has recognised that the prognosis of these patients may not be as good 
as previously believed and recommends studies to define the natural history and outcome of 
patients with non-severe alcoholic hepatitis.10 
 
In an attempt to better identify alcoholic hepatitis patients at highest risk of death, other 
severity scores have been derived from cohort studies including the Glasgow Alcoholic 
Hepatitis Score (GAHS),11 Model for End-stage Liver Disease (MELD)12 and Age Bilirubin 
Creatinine INR (ABIC).13 A GAHS threshold of nine had low sensitivity (54% and 43% at 28- 
and 84-days, respectively) but high specificity (89% and 90% at 28- and 84-days, 
respectively) in predicting mortality.11 A MELD score of > 21 had both sensitivity and 
specificity of 75% in predicting 90-day mortality.12 Two thresholds were applied to the ABIC 
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score; patients with ABIC > 9.0 had 75% risk of death at 90-days compared to 30% with 
ABIC 6.71-9.0 and 0% with ABIC < 6.71.13 Application and comparison of these scores to 
independent cohorts has demonstrated similar predictive accuracy to the DF for early 
mortality.14-16 However, no score is accurate in identifying alcoholic hepatitis patients with the 
lowest risk of mortality (non-severe alcoholic hepatitis). Even patients classified by ABIC < 
6.71 have up to 11% 28-day mortality when applied to an independent cohort.17  
 
Over the last 4 decades, a significant body of literature has been amassed on severe 
alcoholic hepatitis with clearly defined clinical characteristics and short- and medium-term 
survival.18, 19 The most recent individual patient data meta-analysis from 11 RCTs including 
over 2,000 patients described a 19% and 38% mortality at 28 days and 6 months 
respectively.20 Mortality at 1 year was 56% in the largest RCT performed 21 and causes of 
death are well documented.19, 21 In contrast, little is known about the characteristics and 
outcome of patients with less severe alcoholic hepatitis, so called ‘non-severe alcoholic 
hepatitis’, which has been assumed a relatively benign condition with low risk of mortality.  
 
The incidence of non-severe alcoholic hepatitis is uncertain but it is likely that non-severe 
alcoholic hepatitis is more common than its severe form. This is supported by data from the 
STOPAH RCT of prednisolone and pentoxifylline in severe alcoholic hepatitis (DF ≥ 32), in 
which 1103 of 3109 patients with a clinical diagnosis of alcoholic hepatitis who were 
screened met inclusion criteria and were randomised. 2006 screen failures did not meet 
inclusion criteria due to milder disease (DF < 32 or bilirubin < 80 μmol/L).21 
 
The aim of this study was to perform a systematic review and meta-analysis of observational 
studies and clinical trials to determine short (28- and 90-day) and medium (1-year) term 






Data sources and searches 
The systematic review was conducted according to the Preferred Reporting Items for 
Systematic Reviews and Meta-analyses and registered prospectively on the PROSPERO 
database (ID: CRD42018107451). PubMed MEDLINE (1946-2018), EMBASE (1974-2018) 
and Cochrane CENTRAL databases were searched. Abstracts from international liver 
conferences (EASL, AASLD, APASL and DDW) were also searched from 1985 onwards and 
reference lists of included studies were reviewed.  
 
For CENTRAL, the single search term of “alcoholic hepatitis” in title, abstract or keyword was 
used. For MEDLINE, the following keywords were used with (“hepatitis, alcoholic”[MeSH 
Terms] OR (“alcoholic hepatitis”[All Fields])): “mortality”, “survival”, “prognosis”, “biomarker” 
and “outcome”. For EMBASE: “alcoholic hepatitis”[All fields] and the keywords “mortality”, 
“survival”, “prognosis”, “biomarker” and “outcome”. The term “biomarker” was included to 
ensure all studies of clinical biomarkers in non-severe alcoholic hepatitis were included. The 
full search strategy is presented in the supplementary materials. 
 
Study selection 
The population of interest was all alcoholic hepatitis and the primary outcome was mortality. 
Alcoholic hepatitis was defined either by characteristic histological features on liver biopsy or 
by clinical characteristics. Studies that reported histological confirmation of alcoholic 
hepatitis in fewer than half of participants were classified as using a clinical definition of 
alcoholic hepatitis. Studies were included if they reported 28-day, 90-day or 1-year mortality 
after diagnosis for patients with non-severe alcoholic hepatitis. Reports in any language 
were eligible and foreign texts were translated using online translation tools. All study 
designs were eligible including retrospective or prospective observational studies, RCTs or 
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non-randomised clinical trials. Non-severe alcoholic hepatitis was defined as DF < 32, MELD 
< 21,12 ABIC < 6.7113 or bilirubin < 85 μmol/L with histological confirmation. 
 
Data extraction and management 
Two reviewers (AD and KB) independently performed the searches and identified relevant 
papers by review of titles and abstracts. Results were collated and inconsistencies resolved 
by a third reviewer (MC). Information on study design, ethnicity, intervention, definition of 
non-severe alcoholic hepatitis, causes of death and mortality rate at 28 days, 90 days and 1 
year were extracted into pre-piloted forms. In RCTs, mortality in control and intervention 
groups were combined. In papers reporting the same cohort of patients, only the most recent 
report was included. Where outcomes for non-severe alcoholic hepatitis patients were 
reported only in combination with severe alcoholic hepatitis patients, the corresponding 
author of the report was contacted by email on one occasion to provide additional data 
where possible. If no response was obtained, the study was excluded from the analysis. 
 
Risk of bias assessment 
For RCTs, the risk of bias was assessed using the Cochrane risk of bias tool for RCTs22. As 
mortality rates from each arm were pooled, criteria for ramdomisation method, allocation 
method and blinding were not relevant to assess. Each study was assessed as being of 
high, unclear or low risk of bias. For cohort studies, the National Institutes of Health quality 
assessment tool for case series studies23 was chosen as most risk of bias domains validated 
for cohort studies do not apply to this review, which extracted data from patients with non-
severe alcoholic hepatitis from larger cohort studies. The quality of each study was rated as 
poor, fair or good. 
 
Data synthesis and analysis 
For each study, the proportion of non-severe alcoholic hepatitis who had died up to a 
specific time point (28 days, 90 days or 1 year) was given by the number of people dying up 
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to that time point divided by the total number of people diagnosed with non-severe alcoholic 
hepatitis.  Individual study results were combined using a random-effects model.24 The 
overall proportion is a weighted mean where the weight assigned to each study is the 
inverse of the study’s variance. The pooled estimate is calculated after Freeman-Tukey 
double arcsine transformation to stabilise the variances.25 Forest plots of proportions along 
with their 95% confidence intervals were produced for each study and for the overall result.  
We assessed heterogeneity between studies by using I2 test statistic26 and small study 
effects using Egger’s test.27 Substantial heterogeneity was considered to be present if I2 was 
50-90%. Egger’s test was not applied to meta-analyses of less than 10 studies. 
 
Data analysis was conducted using Stata 14.2 (StataCorp. 2015. Stata Statistical Software: 
Release 14. College Station, TX: StataCorp LP). The Metaprop Stata package was used to 
generate the forest plots.28  
 
Subgroup analyses 
No pre-specified subgroup analyses were defined. However, the method of classification of 
non-severe alcoholic hepatitis may define different groups of patients.29 A sensitivity analysis 
excluding studies using classifications other than DF < 32 was performed. Non-severe 
alcoholic hepatitis may be challenging to diagnose on clinical grounds alone and overlaps 
with decompensated chronic alcohol-related liver disease. Therefore, a subgroup analysis 
was performed to determine whether the method of diagnosis of alcoholic hepatitis (clinical 
versus histological) influenced reported mortality. Furthermore, the National Institute of 
Alcoholism and Alcohol Abuse (NIAAA) recently developed well-defined patient selection 
criteria for alcoholic hepatitis studies.9 “Definite” alcoholic hepatitis is clinically diagnosed 
and biopsy proven. “Probable” alcoholic hepatitis has a 90% specificity when defined as: 1) 
alcohol consumption > 40 g/day (females) and > 60 g/day (males) for more than 6 months 
with less than 60 days abstinence before onset of jaundice; 2) onset of jaundice within prior 
8 weeks; 3) AST:ALT > 1.5 and both ALT and AST < 400 IU/L; 4) serum bilirubin > 51 
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µmol/L (3 mg/dL). We conducted a subgroup analysis to determine whether mortality 
differed in studies that included patients with the NIAAA definition of definite or probable 
alcoholic hepatitis compared to other studies.  
 
Retrospective observational studies are prone to bias due to the method of case finding. To 
investigate the effect of study design, an additional comparison of mortality proportions was 
made between prospective and retrospective studies. Studies conducted in patients with 
severe alcoholic hepatitis from non-Caucasian populations have reported high mortality of 
over 50% at 90 days.30, 31 Therefore, a subgroup analysis to determine the influence of 
ethnicity on mortality proportion was performed. A final subgroup analysis was performed to 
evaluate whether mortality proportion differed in studies published in or prior to 2010 





The search strategy identified 2568 unique records. After review of titles and abstracts, 71 
records were relevant and full text manuscripts were obtained and reviewed. Survival data 
for patients with non-severe alcoholic hepatitis were reported in 25 manuscripts (figure 1).5, 
11, 14, 15, 32-52 Additional data from a further four studies were requested by email from the 
corresponding authors. One response was received but no additional data were available for 
that study. Individual study details are outlined in Table S2. 
 
Mortality 
The crude mortality rates of patients with non-severe alcoholic hepatitis was 76/993 (7.6%) 
within 28 days, 75/755 (9.9%) within 90 days and 38/234 (16.2%) within one year. 
Seventeen studies reported the proportion of patients with non-severe alcoholic hepatitis 
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dying within 28-days with estimated mortality in 993 patients of 6% (95% confidence interval 
3-9%; I2=67.3%; p<0.001; figure 2). Fifteen studies in a total of 755 patients reported 90-day 
mortality with overall estimated mortality of 7% (4-11%; I2=64.2%; p<0.001; figure 3). Five 
studies reported the proportion of patients with non-severe alcoholic hepatitis dying within 1 
year. Overall estimated mortality in 234 patients was 13% (4-24%; I2=72%; p=0.006; figure 
4). Substantial heterogeneity was seen in all analyses.  
 
Cause of death 
Three studies specifically reported cause of death in patients with non-severe alcoholic 
hepatitis.39, 44, 45 Of the 13 deaths within one year reported in these studies, eight (62%) were 
liver related, one (8%) due to sepsis and four (30%) due to other causes. The remaining 
studies did not report cause of death or combined all patients with alcoholic hepatitis, 
including severe alcoholic hepatitis.  
 
Study and participant characteristics 
All studies reported the source of data and study design. Gender and age range was missing 
from 76% (19/25) of studies and severity of alcoholic hepatitis (baseline bilirubin, DF, ABIC 
or MELD score) was missing from 80% (20/25) of studies. Multivariable meta-regression was 
not performed given the limited data. Mean or median DF was reported in five studies and 
ranged from 12 to 20 with individual scores between 0.3 and 31 (supplementary table 2). 
Mean or median bilirubin was reported in five studies and ranged from 26 to 140 µmol/L with 
individual values between 3 and 393 µmol/L (supplementary table 2). 
 
Study type and risk of bias assessment 
Of the 25 included studies, 12 were prospective and 13 retrospective in design. Four were 
RCTs of amlodipine,34 corticosteroids,5 vitamin E45 and corticosteroids with oxandrolone.43 
There was one open-label clinical trial of etanercept.44 Median study population size was 46 
(range 3 – 172). Egger’s test of bias from small study effect was not statistically significant 
10 
 
for any analysis (p=0.98 at 28 days and p=0.11 at 90 days). Egger’s test was not valid for 
one-year mortality (only five studies included). Two and ten studies were considered to be at 
high and uncertain risk of bias, respectively. The risk of bias assessment for each study is 
presented in supplementary tables 3 and 4. 
 
Sensitivity and subgroup analyses 
All but four studies categorised patients with non-severe alcoholic hepatitis by DF < 32; two 
used ABIC < 6.71,3, 13 one, bilirubin < 8539 and one, DF < 25.43 A sensitivity analysis 
excluding these studies demonstrated a similar mortality proportion but with lower 
heterogeneity compared to the overall meta-analysis at 28 and 90 days of 7% (4-10%; 
I2=54%; p=0.009) and 8% (4-12%; I2=56%; p=0.007), respectively. Sensitivity analysis for 1-
year mortality proportion was not performed due to the small number of studies after two 
were excluded. 
 
Seven studies required histological confirmation of alcoholic hepatitis for inclusion of 
participants, while 12 used clinical features alone and six, clinical features with histology 
“where available”, which occurred in 3-58% of participants (supplementary table 1). Nine 
studies met the NIAAA criteria for studies in alcoholic hepatitis,9 seven by clinical diagnosis 
and histological confirmation of “definite” alcoholic hepatitis and two by clinical criteria for 
“probable” alcoholic hepatitis. A further four studies met similar criteria with the lower 
bilirubin threshold of 35 µmol/L and three studies required a bilirubin > 80 µmol/L for 
inclusion.  Estimated mortality in studies using histological versus clinical entry criteria were 
similar at day 28 (6% [3-9%; 3 studies] versus 6% [2-10%; I2=73%; p<0.01; 14 studies]) and 
day 90 (5% [1-12%; I2=67%; p=0.01; 6 studies] versus 8% [4-13%; I2=61%; p=0.01; 9 
studies]). Both analyses demonstrated substantial heterogeneity. This subgroup analysis 
was not performed for 1-year mortality proportion due to the small number of studies in each 
group. Subgroup analysis of the nine studies that met NIAAA selection criteria versus other 
studies did not reveal differences in estimated mortality at either 28 or 90 days. At 28 days 
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estimated mortality of NIAAA conforming studies was 3% (0-8%; I2=62%; p=0.02) compared 
to 8% (4-13%; I2=58%; p=0.01) in other studies. At 90 days estimated mortality of NIAAA 
conforming studies was 6% (1-13%; I2=70%; p=0.01) compared to 7% (3-12%; I2=62%; 
p=0.01) in other studies. This subgroup analysis was not repeated for 1-year mortality due to 
the small number of studies. 
 
Prospective versus retrospective study designs showed similar mortality proportions 
between groups. At 28 days, mortality proportion was 1% (0-7%; I2=62%; p=0.02) for six 
prospective studies and 8% (5-12%; I2=46%; p=0.05) for 11 retrospective studies. At 90 
days, mortality proportion was 5% (1-12%; I2=69%; p<0.01) in seven prospective studies 
and 9% (5-13%; I2=54%; p=0.03) in eight retrospective studies. 
 
There has been no significant difference in 28- or 90-day mortality between studies 
performed before or after 2010. At 28 days, studies performed during or before 2010 gave 
an estimated mortality of 4% (0-11%; I2=79%; p<0.001) which was similar to those 
performed after 2010 at 7% (4-11%; I2=36%; p=0.14; p=0.53 between groups). At 90 days, 
estimated mortality was similar in studies performed before 2010 and those performed after 
2010 (6 and 7%, respectively; p=0.60).  
 
Twenty studies were conducted in Caucasian, three in Asian and two in Hispanic 
populations. At 90 days, there was no difference in mortality proportion in studies conducted 
in predominantly Caucasian populations at 9% (5-14%; I2=56%; p=0.02) and non-Caucasian 
populations at 5% (0-15%; I2=57%; p=0.07). This subgroup analysis was not repeated for 








This is the first systematic review and meta-analysis conducted to evaluate the short- and 
medium-term mortality of patients with non-severe alcoholic hepatitis. Mortality at 28 days, 
90 days and 1 year was 6%, 7% and 13% based on data from 993, 755 and 234 patients, 
respectively. Short-term mortality is higher than would be expected from Maddrey’s original 
RCT, which reported no mortality in this group of patients. This 6% 28-day mortality rate is 
comparable to other acute conditions recognised for their mortality risk such as acute 
myocardial infarction with 30-day mortality of 6.2% in the USA53 and community acquired 
pneumonia with 30-day mortality of 4.0% in Western Europe.54 It is also higher than that for 
compensated cirrhosis, which has 5% 1-year mortality and is approaching that of Child Pugh 
B cirrhosis with 20% 1-year mortality.55 However, it is important to note that up to 20% of 
patients with alcoholic hepatitis do not have established cirrhosis,56 suggesting that the acute 
inflammatory process of alcoholic hepatitis itself contributes to increased risk of mortality. 
The limited data available from three studies confirm that the majority of deaths from non-
severe alcoholic hepatitis are liver- or sepsis-related. 
 
In comparison to severe alcoholic hepatitis with 28-day mortality of 19%20 and 1-year 
mortality of more than 50%,21 outcome is undoubtedly better in patients with non-severe 
alcoholic hepatitis. However, 13% 1-year mortality is significant and should become the 
focus of future research. Clear characterisation of both the patients and the condition will 
improve our understanding of the natural history of non-severe alcoholic hepatitis and the 
factors associated with poor outcome. Patients with non-severe alcoholic hepatitis should 
not be automatically excluded from future clinical trials. Indeed, as a trial population, this 
patient group offers an advantage to studying in its own right as patients have less severe 
liver dysfunction, making drug trials safer to conduct and the incidence of non-severe 
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alcoholic hepatitis is likely to be higher than the severe form. Interventional clinical trials are 
called for to improve survival of patients with non-severe alcoholic hepatitis. 
 
Eligible studies were of variable design and quality and several have been reported in 
abstract form only. The primary analyses all had substantial heterogeneity reflecting the 
differences in study design, inclusion criteria or definition of non-severe alcoholic hepatitis. 
There was a large proportion of single centre retrospective observational studies (9/25), and 
many of the studies (12/25) were evaluated to be of uncertain or high risk of bias. However, 
subgroup analysis by study design (prospective versus retrospective) did not reveal any 
significant difference in survival proportions at 28 or 90 days. 
 
We acknowledge the challenges in making a definitive diagnosis of alcoholic hepatitis and in 
differentiating non-severe alcoholic hepatitis from decompensated chronic alcohol-related 
liver disease solely by clinical features. Seven studies required histological confirmation of 
alcoholic hepatitis and met NIAAA criteria9 for “definite” alcoholic hepatitis and a further two 
applied stringent clinical criteria to allow diagnosis of “probable” alcoholic hepatitis.9 
However, most studies were conducted prior to the publication of these criteria, which have 
now become widely adopted in clinical trials. To test whether the method of diagnosis of 
alcoholic hepatitis influenced the result of the meta-analysis, we performed a subgroup 
analysis comparing studies with histological versus clinical entry criteria as well as NIAAA 
criteria conforming and non-conforming studies, which both demonstrated similar mortality at 
28 and 90 days. We are therefore confident that the mortality estimates do indeed relate to 
patients with non-severe alcoholic hepatitis. 
 
There were limited data available on severity, measured either by DF or bilirubin level, which 
were only reported in five studies. Average DF ranged from 12 to 20 and average bilirubin 
from 26 to 140 µmol/L, although it is noted that lower values came from two studies requiring 
histological confirmation of the diagnosis. Despite such a range of severity, all studies only 
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included hospitalised patients with a prolonged history of heavy alcohol consumption, which 
remains a relevant group of patients in current clinical practice. However, both the wide 
spectrum of disease and differing patient selection criteria for each study limit the 
generalisability of this meta-analysis. These findings emphasise the need for a prospective 
study to collect detailed information on the characteristics and outcomes of patients with 
non-severe alcoholic hepatitis defined by stringent criteria such as those of the NIAAA.9 This 
would also provide the opportunity to develop tools to improve the accuracy of scoring 
systems to predict mortality in patients with non-severe alcoholic hepatitis. 
 
Early mortality rates, at both 28 and 90 days, reported in older studies (pre-2010) were 
similar to more recent studies. This concurs with a meta-analysis of mortality in all patients 
with alcoholic hepatitis, which did not show a change in 28- or 180-day mortality over time.57 
Despite improvements in the management of acutely unwell patients over the last four 
decades, this steady rate of mortality over time emphasises the need to concentrate 
attention on patients with non-severe alcoholic hepatitis to develop methods to improve their 
outcome. 
 
Twenty studies were conducted in predominantly Caucasian populations and five in Asian or 
Hispanic populations but individual studies did not report survival outcome by ethnicity. 
Subgroup analysis by ethnicity did not demonstrate differences in survival proportions at 90 
days. However, the meta-analysis findings have limited applicability to non-Caucasian 
populations.  
 
Several different definitions of non-severe alcoholic hepatitis were applied in the included 
studies but DF < 32 was most commonly used (20/25). A sensitivity analysis excluding other 
definitions did not show any differences in the proportion surviving at 28 and 90 days. Only 
five studies with a total of 234 patients provided data on 1-year survival using three different 




Only six out of 25 eligible studies reported information on patient characteristics. Thus, 
multivariable meta-regression was not appropriate. Selection bias is likely as at least three 
studies included only male subjects.39, 43, 50 
 
Given the clinical and research emphasis on severe alcoholic hepatitis only, patient selection 
bias and reporting bias are likely. All 13 retrospective observational studies included patients 
identified through hospital diagnosis coding or histopathology results, which are both 
susceptible to excluding less severe forms of alcoholic hepatitis. Of the 25 eligible studies, 
only two studies (one prospective RCT45 and one retrospective observational study in 




This systematic review and meta-analysis demonstrates that “non-severe” alcoholic hepatitis 
is poorly named and challenges the assumption that it is a benign condition. “Moderate” 
alcoholic hepatitis is a more apt descriptor. The significant burden of mortality, which has not 
improved over time, of 6% within 28 days and 13% at one year needs to be addressed. This 
systematic review has highlighted the paucity of high quality studies dedicated to this patient 
group. Consistent with a recent expert consensus statement,10 we recommend further 
studies in a well-defined group of patients with non-severe alcoholic hepatitis to determine 
patient characteristics, long-term outcome and cause of death. This group of patients should 
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Figure 1. Results from literature search for studies relating to non-severe alcoholic hepatitis 
published prior to July 2018. 
 
Figure 2. Forest plot of 28-day mortality of patients with non-severe alcoholic hepatitis 
showing estimated mortality, 95% confidence intervals (CI) and contribution to meta-analysis 
(% weight). 
 
Figure 3. Forest plot of 90-day mortality of patients with non-severe alcoholic hepatitis 
showing estimated mortality, 95% confidence intervals (CI) and contribution to meta-analysis 
(% weight). 
 
Figure 4. Forest plot of 1-year mortality of patients with non-severe alcoholic hepatitis 
showing estimated mortality, 95% confidence intervals (CI) and contribution to meta-analysis 
(% weight). 
 
 
 
 
 
 
